Document Detail


Biomarkers in spondyloarthritis.
MedLine Citation:
PMID:  20714832     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Key challenges in the management of spondyloarthritis focus on the lack of availability of measures of disease activity and the inability to predict joint damage or response to treatment, which is expensive and associated with potentially serious toxicity. Recent studies have focused on the possible contribution of soluble biomarkers, which have been selected based on current understanding of their role in inflammation and/or their association with turnover of joint matrix. Emerging candidates for disease activity markers include interleukin-6 and soluble cytotoxic T lymphocyte associated molecule-4. Potential predictors of damage include metalloproteinase-3 and sclerostin. Acute-phase reactants C-reactive protein and serum amyloid A and interleukin-6 are currently the best predictors of treatment response. Significant study limitations are small sample size and the lack of multivariate analyses that can determine whether the biomarker contributes information that is independent of other clinical and laboratory variables used in routine care.
Authors:
Walter P Maksymowych
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current rheumatology reports     Volume:  12     ISSN:  1534-6307     ISO Abbreviation:  Curr Rheumatol Rep     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-08-25     Completed Date:  2010-12-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100888970     Medline TA:  Curr Rheumatol Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  318-24     Citation Subset:  IM    
Affiliation:
Department of Medicine, University of Alberta, 562 Heritage Medical Research Building, Edmonton, AB, T6G 2S2, Canada. walter.maksymowych@ualberta.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute-Phase Proteins / metabolism,  urine
Antigens, CD / blood,  urine
Biological Markers / blood*,  urine*
Bone Morphogenetic Proteins / blood,  urine
Disease Progression
Genetic Markers
Humans
Inflammation / blood,  physiopathology,  urine
Interleukin-6 / blood,  urine
Matrix Metalloproteinase 3
Spondylarthritis / blood*,  physiopathology,  therapy,  urine*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Acute-Phase Proteins; 0/Antigens, CD; 0/Biological Markers; 0/Bone Morphogenetic Proteins; 0/Genetic Markers; 0/Interleukin-6; 0/SOST protein, human; 0/cytotoxic T-lymphocyte antigen 4; EC 3.4.24.17/Matrix Metalloproteinase 3

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Readiness: the state of the science (or the lack thereof).
Next Document:  Hemodynamic rounds: Ascending aortic dissection as a mechanism of hemodynamic instability.